FDA Grants Priority Review to Aducanumab, Biogen’s New Alzheimer’s Treatment

The FDA has accepted Biogen’s application for aducanumab, an investigational treatment for Alzheimer’s, and even granted it Priority Review, with an action date set for March 7, 2021. Learn more.

Read more »

Back To Blog